Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Liabilities (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Total Liabilities data on record, last reported at $133.7 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 0.61% year-over-year to $133.7 million; the TTM value through Sep 2025 reached $133.7 million, down 0.61%, while the annual FY2024 figure was $131.4 million, 0.94% up from the prior year.
  • Total Liabilities reached $133.7 million in Q3 2025 per BTAI's latest filing, roughly flat from $133.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $154.7 million in Q1 2024 and bottomed at $17.0 million in Q1 2022.
  • Average Total Liabilities over 4 years is $122.5 million, with a median of $131.4 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: surged 646.54% in 2023, then dropped 16.77% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $129.1 million in 2022, then grew by 0.88% to $130.2 million in 2023, then increased by 0.94% to $131.4 million in 2024, then increased by 1.73% to $133.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $133.7 million in Q3 2025, $133.5 million in Q2 2025, and $128.7 million in Q1 2025.